Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CART22/CART22-65s Cells by Novartis for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
CART22/CART22-65s Cells is under clinical development by Novartis and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...